Market Research Logo

Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, H2 2016

Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Focal Segmental Glomerulosclerosis – Pipeline Review, H2 2016, provides an overview of the Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline landscape.

Focal Segmental glomerulosclerosis is a rare disease that attacks the kidney’s filtering units (glomeruli) causing serious scarring which leads to permanent kidney damage and even failure. Symptoms include proteinuria, edema, high cholesterol, high blood pressure and poor appetite. Risk factors include infection, obesity, sickle cell disease and reflux nephropathy. Treatment includes antibiotics, vitamin D supplements, and immunosuppressive drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Focal Segmental Glomerulosclerosis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Focal Segmental Glomerulosclerosis (FSGS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Focal Segmental Glomerulosclerosis (FSGS) Overview
Therapeutics Development
Pipeline Products for Focal Segmental Glomerulosclerosis (FSGS) - Overview
Pipeline Products for Focal Segmental Glomerulosclerosis (FSGS) - Comparative Analysis
Focal Segmental Glomerulosclerosis (FSGS) - Therapeutics under Development by Companies
Focal Segmental Glomerulosclerosis (FSGS) - Therapeutics under Investigation by Universities/Institutes
Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Focal Segmental Glomerulosclerosis (FSGS) - Products under Development by Companies
Focal Segmental Glomerulosclerosis (FSGS) - Products under Investigation by Universities/Institutes
Focal Segmental Glomerulosclerosis (FSGS) - Companies Involved in Therapeutics Development
Complexa Inc
Dimerix Bioscience Pty Ltd
GlaxoSmithKline Plc
Retrophin Inc
Shire Plc
Variant Pharmaceuticals Inc
Focal Segmental Glomerulosclerosis (FSGS) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(irbesartan + propagermanium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CXA-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
losmapimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHP-627 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sparsentan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-5484 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAR-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Focal Segmental Glomerulosclerosis (FSGS) - Dormant Projects
Focal Segmental Glomerulosclerosis (FSGS) - Discontinued Products
Focal Segmental Glomerulosclerosis (FSGS) - Product Development Milestones
Featured News & Press Releases
Nov 30, 2016: World Renowned Experts Join Variant Pharmaceuticals' Scientific Advisory Board
Nov 21, 2016: Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016
Nov 19, 2016: Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016
Oct 21, 2016: Retrophin to Present Additional Data from Phase 2 DUET Study of Sparsentan in Late-Breaking Oral Session at ASN Kidney Week 2016
Sep 07, 2016: Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis
Aug 01, 2016: Dimerix announces outcomes of DMX-200 pre-IND meeting with the FDA
Mar 30, 2016: Retrophin Completes Enrollment of Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis
Dec 14, 2015: Dimerix receives Orphan Designation for its lead drug candidate targeting patients with chronic kidney disease
Nov 16, 2015: Retrophin Receives European Orphan Drug Designation for Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
Jan 09, 2015: Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan
Feb 25, 2013: Ligand Receives $1.4m Milestone Payment From Retrophin
Jan 09, 2013: Ligand Receives Equity Milestone Payment From Retrophin
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS), H2 2016
Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by Complexa Inc, H2 2016
Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016
Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by GlaxoSmithKline Plc, H2 2016
Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by Retrophin Inc, H2 2016
Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by Shire Plc, H2 2016
Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by Variant Pharmaceuticals Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Focal Segmental Glomerulosclerosis (FSGS) - Dormant Projects, H2 2016
Focal Segmental Glomerulosclerosis (FSGS) - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS), H2 2016
Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report